Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    News from ASH 2020: 'Practice-changing' results with ruxolitinib in chronic GVHD and no benefit seen with tranexamic acid in patients with blood cancers and severe thrombocytopenia

    News from ASH 2020: 'Practice-changing' results with ruxolitinib in chronic GVHD and no benefit seen with tranexamic acid in patients with blood cance…

    FromBlood & Cancer

    Start listeningView podcast show

    News from ASH 2020: 'Practice-changing' results with ruxolitinib in chronic GVHD and no benefit seen with tranexamic acid in patients with blood cance…

    FromBlood & Cancer

    ratings:
    Length:
    10 minutes
    Released:
    Dec 15, 2020
    Format:
    Podcast episode

    Description

    News from ASH 2020: No benefit from tranexamic acid prophylaxis in blood cancers: https://bit.ly/2K3Mah1 ‘Practice changing’: Ruxolitinib as second-line in chronic GVHD: https://bit.ly/3gT4kyg  Durable responses with anti-BCMA CAR T-cell for multiple myeloma: https://bit.ly/381f1ut Five-minute SC injection of daratumumab in RRMM: https://bit.ly/3gKuZgx Email Blood & Cancer at podcasts@mdedge.com  
    Released:
    Dec 15, 2020
    Format:
    Podcast episode

    Titles in the series (100)

    The official podcast feed of MDedge Hematology-Oncology, part of the Medscape Professional Network. On Thursdays, Dr. David Henry interviews key opinion leaders and rising stars in hematology and oncology. The information in this podcast is provided for informational and educational purposes only.